Health breakthroughs and money matters, in plain words

Home » FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653

FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653

By

–

FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653

The US Food and Drug Administration has proposed reclassifying immunohistochemistry companion diagnostics from Class III to Class II, a move that would slash the premarket filing fee from $636,732 to $28,653 and eliminate a $22,286 annual reporting fee. The proposal covers 12 product codes for tissue tests used with approved cancer drugs and follows a petition from Ventana Medical Systems, a Roche subsidiary, asking the agency to move PD-L1 tests to the lower-risk category.

What Companion Diagnostics Do

A companion diagnostic is a test that identifies patients eligible for a specific targeted therapy. In immunohistochemistry, a pathologist takes a thin slice of tumor tissue, stains it with an antibody that binds to a specific protein, and examines the slide under a microscope. If the protein is present, the linked drug may work; if absent, the drug may be ineffective, sparing the patient months of futile treatment and side effects. Common examples include HER2 testing for breast cancer, PD-L1 for immunotherapy, and ALK for lung cancer. The first such test, the Dako HercepTest for HER2, was approved on September 25, 1998.

Why They Were Class III

These tests entered Class III not because of a risk assessment, but by statutory default. Any device type not on the market before May 28, 1976, is automatically placed in Class III, the category reserved for the highest-risk devices such as heart valves and implants, and remains there until the FDA acts to reclassify it. For 28 years, a stain on a glass slide has shared a regulatory lane with implantable devices, requiring a premarket approval application, the agency’s most rigorous and costly review pathway.

The Safety Record

The FDA’s own data support the reclassification. Since 1998, the agency has approved 22 original applications and approximately 270 supplements for these tests. The adverse-event database contains 48 reports across that period, and there has never been a Class I recall, the most serious type. The encouraging part is that the real-world safety profile aligns with a moderate-risk classification rather than the highest-risk tier.

The Cost Barrier

The financial difference between the two pathways is stark. For fiscal 2027, a premarket approval application carries a fee of $636,732. A 510(k) notification, the standard pathway for Class II devices, costs $28,653, just 4.5 percent of the PMA fee. Class III products also incur a $22,286 annual reporting fee that would disappear under Class II. These costs are ultimately borne by patients and health systems through test pricing and access limitations. Early findings suggest that lowering the regulatory toll could encourage more developers to bring forward new companion diagnostics, expanding the menu of tests that match patients to targeted therapies.

Industry Dynamics

The catalyst was a petition filed by Ventana Medical Systems on January 7, 2026, requesting reclassification of PD-L1 tissue assays. The FDA expanded the scope on its own initiative to cover all 12 product codes for cancer-drug tissue tests of this type. Ventana and Dako (now part of Agilent) have historically dominated this market. An incumbent requesting a lower barrier raises questions about competitive dynamics, though the FDA’s broader proposal suggests the agency sees the safety evidence as sufficient across the entire category.

What Comes Next

Comments on the proposal are due January 11, 2027. The last reclassification in this series took 432 days from proposal to final order, and the FDA has indicated it aims to complete the program by November 2027. Patients should talk to their doctor or oncologist about which companion diagnostic tests are appropriate for their specific cancer type and treatment plan.

Sources

Photo: Mezidi Zineb / Unsplash (Unsplash License)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News